[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2850871B1 - Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament - Google Patents

Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament

Info

Publication number
FR2850871B1
FR2850871B1 FR0301440A FR0301440A FR2850871B1 FR 2850871 B1 FR2850871 B1 FR 2850871B1 FR 0301440 A FR0301440 A FR 0301440A FR 0301440 A FR0301440 A FR 0301440A FR 2850871 B1 FR2850871 B1 FR 2850871B1
Authority
FR
France
Prior art keywords
phenothiazine
methylamino
cyano
propyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0301440A
Other languages
English (en)
Other versions
FR2850871A1 (fr
Inventor
Michel Dib
Ahcene Hameg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0301440A priority Critical patent/FR2850871B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to ES04709051T priority patent/ES2319991T3/es
Priority to PCT/US2004/003480 priority patent/WO2004071512A1/fr
Priority to EP04709051A priority patent/EP1626727B1/fr
Priority to JP2006503382A priority patent/JP4828406B2/ja
Priority to CA002513920A priority patent/CA2513920A1/fr
Priority to AT04709051T priority patent/ATE418987T1/de
Priority to DE602004018765T priority patent/DE602004018765D1/de
Priority to US10/773,480 priority patent/US7538106B2/en
Publication of FR2850871A1 publication Critical patent/FR2850871A1/fr
Application granted granted Critical
Publication of FR2850871B1 publication Critical patent/FR2850871B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
FR0301440A 2003-02-07 2003-02-07 Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament Expired - Fee Related FR2850871B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0301440A FR2850871B1 (fr) 2003-02-07 2003-02-07 Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament
PCT/US2004/003480 WO2004071512A1 (fr) 2003-02-07 2004-02-06 Utilisation, en tant que medicament, de 2-cyano-10-(2-methyl-3-(methylamino)-propyl) phenothiazine ou un sel de celui-ci pharmaceutiquement acceptable
EP04709051A EP1626727B1 (fr) 2003-02-07 2004-02-06 Utilisation, en tant que medicament de 2-cyano-10-(2-methyl-3-(methylamino)-propyl) phenothiazine ou un sel de celui-ci pharmaceutiquement acceptable
JP2006503382A JP4828406B2 (ja) 2003-02-07 2004-02-06 ２−シアノ−１０−（２−メチル−３−（メチルアミノ）−プロピル）フェノチアジンまたはその製薬上受容できる塩の医薬としての使用
ES04709051T ES2319991T3 (es) 2003-02-07 2004-02-06 Uso de 2-ciano-10-(2-metil-3-(metilamino)-propil)fenotiazina o su sal farmaceuticamente aceptable como un medicamento.
CA002513920A CA2513920A1 (fr) 2003-02-07 2004-02-06 Application de 2-cyano-10-(methyl-3(methylamino)- propyl)phenothiazine ou d'un sel pharmaceutiquement acceptable comme medicament
AT04709051T ATE418987T1 (de) 2003-02-07 2004-02-06 Verwendung von 2-cyano-10- (2-methyl-3- (methylamino)- propyl)-phenothiazin oder einem pharmazeutisch akzeptablen salz davon als arzneimittel
DE602004018765T DE602004018765D1 (de) 2003-02-07 2004-02-06 Verwendung von 2-cyano-10- (2-methyl-3- (methylamino)- propyl)-phenothiazin oder einem pharmazeutisch akzeptablen salz davon als arzneimittel
US10/773,480 US7538106B2 (en) 2003-02-07 2004-02-06 Application of 2-cyano-10- (2-methyl-3- (methylamino)- propyl) phenothiazine or a pharmaceutically acceptable salt as medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301440A FR2850871B1 (fr) 2003-02-07 2003-02-07 Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament

Publications (2)

Publication Number Publication Date
FR2850871A1 FR2850871A1 (fr) 2004-08-13
FR2850871B1 true FR2850871B1 (fr) 2006-07-14

Family

ID=32731855

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0301440A Expired - Fee Related FR2850871B1 (fr) 2003-02-07 2003-02-07 Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament

Country Status (3)

Country Link
US (1) US7538106B2 (fr)
JP (1) JP4828406B2 (fr)
FR (1) FR2850871B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL97951C (fr) * 1955-11-15
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique

Also Published As

Publication number Publication date
US20040171610A1 (en) 2004-09-02
FR2850871A1 (fr) 2004-08-13
US7538106B2 (en) 2009-05-26
JP4828406B2 (ja) 2011-11-30
JP2007525419A (ja) 2007-09-06

Similar Documents

Publication Publication Date Title
HUS1400011I1 (hu) Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére
CY2014019I2 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
NO20033594L (no) Fenetanolamin-derivater for behandling av luftveissykdommer
IL173145A (en) Use of a pak inhibitor for the production of a medicament for the treatment of a joint disease
CY2017014I1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
IL219818A0 (en) Pharmaceutically acceptable salts of quinolinone compounds improved pharmaceutical properties
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
NO20033343L (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
WO2008020040A3 (fr) Utilisation de composés et de dérivés de 2,5-dihydroxybenzène pour le traitement de la fibrose
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2007038112A3 (fr) Composition pharmaceutique conçue pour ameliorer la fonction cognitive
IL159379A0 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
EG23547A (en) Preparation of a topical pharmaceutical preparation of curcumin alone or a combination of circumin plus capsaicin as an effective remedy for treatmentof peripheral neuropathies
FR2850871B1 (fr) Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
TWI349549B (en) Medicament for treatment of intraocular angiopoietic disease
HK1094153A1 (en) Nasal pharmaceutical composition of piribedil
HK1077572A1 (en) Pharmaceutical salts of reboxetine
WO2005082884A3 (fr) Composes
EP1551456A4 (fr) Composition pharmaceutique servant a prevenir et a traiter des maladies renales
HK1077216A1 (en) Use of thiazole derivatives for the manufacture ofa medicament for the treatment of chronic obstruc tive pulmonary disease
AU2003214317A1 (en) Use of a novel class of drugs for the treatment of parasitic diseases
FR2867979B1 (fr) Nouvelle application therapeutique d'un derive de la phenothiazine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20181031